Research Advances in Heart Failure: A Compendium

  title={Research Advances in Heart Failure: A Compendium},
  author={Eugene Braunwald},
  journal={Circulation Research},
  • E. Braunwald
  • Published 30 August 2013
  • Medicine
  • Circulation Research
Without question, the past half century has witnessed spectacular advances in cardiovascular medicine and surgery. In the United States, a full two thirds of the 6-year prolongation of life that has occurred has been a direct consequence of these advances1 that did not spring forth simply from the heads of brilliant, insightful clinicians. Instead, most advances were based on preclinical research that were then translated into improvements in clinical care.2 For instance, the microbiologists… 

Recent Developments in Heart Failure.

Some recent progress in understanding the pathobiology of HF and advances in conceptual approaches for future treatments are highlighted, to focus the readers’ attention on some of the more exciting and daring areas of cardiovascular research.

New therapies for the treatment of heart failure: a summary of recent accomplishments

A novel therapeutic approach could restore stable heart function either by restoring depleted membrane proteins or by balancing the intracellular calcium concentration, which is still highly likely to succeed.

From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure.

Concise Review: Mending a Broken Heart: The Evolution of Biological Therapeutics

A review of the recent advances in cell‐ and gene‐based therapies in the context of cardiovascular disease, emphasizing the most advanced therapies and highlighting the emerging technologies that hold promise to revolutionize the biological therapies for cardiovascular diseases.

Artificial Hearts and Cardiac Assist Devices: The Spectrum of the New Era

This chapter aims to provide a broad perspective on the evolving state of the art regarding ventricular assist device and artificial heart technology and on the effects these newer methods are having on current clinical patterns, post-implant outcomes, and device-related technical complications in patients with various modern implantable total artificial hearts and continuous-flow left ventricular Assist devices.

Heart failure with preserved ejection fraction in the elderly: scope of the problem.

Pleiotropic mechanisms of action of perhexiline in heart failure

The re-purposing of the anti-anginal drug perhexiline has resulted in symptomatic improvements in heart failure patients and the inhibition of carnitine palmitoyltransferase-1 (CPT-1) has been proposed as the primary mechanism underlying the therapeutic benefit of PHX.

Early in vivo experience with the pediatric continuous-flow total artificial heart.

  • J. KarimovD. Horvath K. Fukamachi
  • Medicine, Engineering
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • 2018

Oxidative Stress and Heart Failure

The evidence for ROS-induced myocardial damage during HF progression is focused on and some potential pharmacological interventions and strategies for reducing the damage are addressed.



Cardiac Resynchronization Therapy: State of the Art.

Cell Therapy for Heart Failure: A Comprehensive Overview of Experimental and Clinical Studies, Current Challenges, and Future Directions

A critically review of the large body of work performed with respect to the use of stem/progenitor cells in HF, both at the experimental and clinical levels, and to discuss current controversies, unresolved issues, challenges, and future directions.

Adrenergic Nervous System in Heart Failure: Pathophysiology and Therapy

The present review discusses the role of the ANS in cardiac physiology and in HF pathophysiology, the mechanisms of regulation of ANS activity and how they go awry in chronic HF, methods of measuring AnS activity in HF, the molecular alterations in heart physiology that occur inHF, along with their pharmacological and therapeutic implications, and, finally, drugs and other therapeutic modalities used in HF treatment that target or affect the ANs and its effects on the failing heart.

The failing heart--an engine out of fuel.

  • S. Neubauer
  • Medicine
    The New England journal of medicine
  • 2007
This review describes cardiac energy metabolism, appraises the methods used for its assessment, evaluates the role of impaired energy metabolism in heart failure, and gives options for metabolic therapy.

Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history.

This review provides an historical and personal perspective on the discovery of genetic causes for hypertrophic cardiomyopathy (HCM) and a thematic review series that will present contemporary advances in the field of hypertrophic heart disease.


A study of the entire family, able to trace all members of the family for two generations, totalling 23 persons, found evidence of heart disease in the three sibs.

Heart Failure Gene Therapy: The Path to Clinical Practice

The objective of this review is to discuss the current state of the art in the field and point out inevitable innovations on which the future evolution of heart failure gene therapy into an effective and safe clinical treatment relies.

Reversal of Severe Heart Failure With a Continuous-Flow Left Ventricular Assist Device and Pharmacological Therapy: A Prospective Study

Reversal of end-stage heart failure secondary to nonischemic cardiomyopathy can be achieved in a substantial proportion of patients with nonpulsatile flow through the use of a combination of mechanical and pharmacological therapy.

Molecular changes after left ventricular assist device support for heart failure.

  • E. Birks
  • Medicine, Biology
    Circulation research
  • 2013
The molecular changes occurring after LVAD support are reviewed, both those demonstrated with LVAD unloading alone in patients bridged to transplantation and those occurring in the myocardium of patients who have recovered enough myocardial function to have the device removed.

A receptor-mediated pathway for cholesterol homeostasis.

The approach was to apply the techniques of cell culture to unravel the postulated regulatory defect in FH, which led to the discovery of a cell surface receptor for a plasma cholesterol transport protein called low density lipoprotein (LDL) and to the elucidation of the mechanism by which this receptor mediates feedback control of cholesterol synthesis.